Literature DB >> 7489410

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

T W Chun1, D Finzi, J Margolick, K Chadwick, D Schwartz, R F Siliciano.   

Abstract

Although it is presumed that the integration of HIV-1 into the genome of infected CD4+ T lymphocytes allows viral persistence, there has been little direct evidence that CD4+ T cells with integrated provirus function as a latent reservoir for HIV-1 in infected individuals. Using resting CD4+ T-cell populations of extremely high purity and a novel assay that selectively and unambiguously detects integrated HIV-1, we show that resting CD4+ T cells harbouring integrated provirus are present in some infected individuals. However, these cells do not accumulate within the circulating pool of resting CD4+ T cells in the early stages of HIV-1 infection and do not accumulate even after prolonged periods in long-term survivors of HIV-1 infection. These results suggest that because of viral cytopathic effects and/or host effector mechanisms, productively infected CD4+ T cells do not generally survive for long enough to revert to a resting memory state in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489410     DOI: 10.1038/nm1295-1284

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  367 in total

1.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

2.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  Reservoirs for HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

4.  Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA.

Authors:  N Vandegraaff; R Kumar; C J Burrell; P Li
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Latency and viral persistence in HIV-1 infection.

Authors:  J D Siliciano; R F Siliciano
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

6.  Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

Authors:  T Pierson; T L Hoffman; J Blankson; D Finzi; K Chadwick; J B Margolick; C Buck; J D Siliciano; R W Doms; R F Siliciano
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Authors:  Frank Wolschendorf; Alexandra Duverger; Jennifer Jones; Frederic H Wagner; Jason Huff; William H Benjamin; Michael S Saag; Michael Niederweis; Olaf Kutsch
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

8.  Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells.

Authors:  Nitasha A Kumar; Renee M van der Sluis; Talia Mota; Rachel Pascoe; Vanessa A Evans; Sharon R Lewin; Paul U Cameron
Journal:  J Immunol       Date:  2018-07-20       Impact factor: 5.422

9.  Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.

Authors:  Theodore C Pierson; Yan Zhou; Tara L Kieffer; Christian T Ruff; Christopher Buck; Robert F Siliciano
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.